#Mycoplasma Testing Marketgrowth

[sarahbennu01]

Analysis on Impact of COVID19-Global Mycoplasma Testing Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and ATCC

The global mycoplasma testing market size is expected to grow by USD 445.57 million as per Technavio. This marks a significant market growth compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. Moreover, steady growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of over 11%.

Request for Technavio's latest reports on directly and indirectly impacted markets Market estimates include pre- and post-COVID-19 impact on the mycoplasma testing market -

Download free sample report

The global outbreak of COVID-19 has compelled several companies in the healthcare industry to focus on finding a cure for this life-threatening disease. The number of pharmaceutical and biotechnology companies that focus on biomedical research is increasing, resulting in rising demand for mycoplasma testing to identify and eliminate mycoplasma contamination during the development of cell-derived biological and pharmaceutical products. However, the global outbreak of coronavirus is expected to have a neutral impact on the growth of the mycoplasma testing market during the forecast period.

The market is driven by the increasing focus on R&D of biopharmaceuticals. In addition, the growing M&A and partnerships between CROs, and pharmaceutical and biotechnology companies is anticipated to boost the growth of the mycoplasma testing market.

New class therapeutics such as cell therapy and gene therapy are gaining popularity as a novel treatment for many chronic and acute diseases. Thus, many pharmaceutical companies and research institutes are concentrating on the R&D of these products owing to their huge market potential. However, cell therapy products witness challenges around sterilization and its storage, as a result of which, it has to be immediately administered to the patients. Common mycoplasma species such as Acholeplasma laidlawii, Mycoplasma arginini, Mycoplasma bovis, Mycoplasma fermentans, and Mycoplasma salivarium have been identified as contamination in cell cultures and the biopharmaceutical processes. A product developed with mycoplasma contamination triggers serious side effects in humans. This is driving the demand for mycoplasma test kits. Rapid mycoplasma test kits are commercially available in the market that can be used in research labs and biopharmaceutical manufacturing companies for cell line qualification and in-process monitoring.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Mycoplasma Testing Companies:

Agilent Technologies Inc.

Agilent Technologies Inc. has business operations under various segments, such as life sciences and applied markets, diagnostics and genomics, and Agilent CrossLab. The company's key offerings include MycoSensor PCR Assay Kit, 50 Rxn, which is a gel-based PCR assay that can rapidly detect mycoplasma infections in the human cell lines in less than four hours.

ATCC

ATCC operates its business through various segments, such as classic media, specialty media, stem cell research, human cytogenetics, mycoplasma detection, and molecular biology. The company's key products include Universal Mycoplasma Detection Kit, which offers a quick and sensitive PCR-based test to detect mycoplasma contaminants in cell culture.

Becton, Dickinson and Co.

Becton, Dickinson and Co. has business operations under various segments, such as BD Medical, BD Life Sciences, and BD Interventional. The company's key offerings include BD MAX System, which is a fully-integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. operates its business through two segments: pharmaceuticals and diagnostics. The company's key offerings include MycoTOOL PCR Mycoplasma Detection Kit, which tests the absence of mycoplasma in cell culture samples. It supplies all reagents for the amplification step. It is an in-vitro amplification test optimized for detection of mycoplasma in cell culture.

InvivoGen

InvivoGen has business operations under various segments, such as research fields, biological tools, and custom services. The company offers PlasmoTest, which is the first assay to utilize cells to signal the presence of mycoplasma. It is a simple, rapid, and reliable assay for the visual detection of mycoplasma contamination in cell cultures.

[akashthings]

Global  Viral Transport Media MarketGrowth Statistics, Latest Trends & Future Prospects2020-2026

Summary - A Global Viral Transport Media Market and Regional Forecasts 2020-2027-” has been featured on WiseGuyReports.

lobal Viral Transport Media Market is valued at approximately USD XXX million in 2019 and is anticipated to grow with a healthy growth rate of more than XXX% over the forecast period 2020-2027. Viral transport media (VTM) is a collection and transport system mainly used for the collection, transport, and long-term freezing of biological specimens containing viruses, such as COVID-19, chlamydia, ureaplasma organisms, or mycoplasma

ALSO READ: https://www.openpr.com/news/2111031/global-viral-transport-media-market-2020-industry-analysis

They often used in collecting nasal swab and throat swabs to collect samples. The sample is later on sent to clinical laboratories in transport medium for detection and identification, to check the presence of a virus in the human body. With the recent outbreak of COVID-19 pandemic throughout the world, the demand for viral transport media is significantly growing to obtain the information and collection of novel coronavirus samples. The sample is usually collected in VTM to regulate the stability of the sample & get transported in a cold chain. Therefore, the increasing prevalence of COVID-19 around the world is one of the major factors driving the adoption of viral transport media all over the world. According to the World Health Organization (WHO), as of March 7th March 2020, around 87,831 confirmed cases of coronavirus registered throughout the world, including 3,549 deaths, and is reached to almost 7,941,791 confirmed cases with 434,796 deaths by 16th June 2020. According to the WHO, America is the leading country in terms of COVID patients and death, with almost 2,079, 592 confirmed cases with 115,484 deaths as of 16th June 2020. This, in turn, is expected to leverage the demand for viral transport media around the world. Moreover, the increasing number of government initiatives for testing kits in the developed & developing countries, along with the increasing number of product launches by the market vendors is further accelerating the market growth over the forecast period. However, technical issues related to swabs collection is one of the major factors impeding the market growth over the forecast period of 2020-2027.

 The regional analysis of the global Viral Transport Media market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the growing number of diagnostic tests, coupled with the rising prevalence of infectious disease in the region. Whereas, Asia-Pacific is anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027. Factors such as the rising demand for sample collection kits, along with the increasing healthcare spending would create lucrative growth prospects for the Viral Transport Media market across the Asia-Pacific region.

 Major market player included in this report are:

Thermo Fisher Scientific Inc.

Puritan Medical Products, BD

Laboratory Corporation of America

Lucence Diagnostics Pte Ltd.

Hardy Diagnostics

Formlabs

Medline Industries, Inc.

VIRCELL S.L.

HiMedia Laboratories

Titan Biotech Ltd.

 The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

 By Application:

Diagnosis of Certain Viral Infections

Preclinical Testing

 By End-Use:

Microbiology Laboratories

Diagnostic Laboratories

Hospitals & Clinics

Home Test

Others

 By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

 Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

 Furthermore, years considered for the study are as follows:

 Historical year – 2017, 2018

Base year – 2019

Forecast period – 2020 to 2027

 Target Audience of the Global Viral Transport Media Market in Market Study:

 Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

...FOR MORE DETAILS: https://www.wiseguyreports.com/reports/5626798-global-viral-transport-media-market-size-study-by

 About Us:

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.                

 Contact Us:

NORAH TRENT                                                      

sales@wiseguyreports.com       

Ph: +162-825-80070 (US)                          

Ph: +44 203 500 2763 (UK)